A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs Aripiprazole/sertraline (Primary) ; Sertraline
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 16 Apr 2018 Primary endpoint [Montgomery-Asberg Depression Rating Scale (MADRS)] has been met, according to the results published in the Psychiatry and Clinical Neurosciences.
- 16 Apr 2018 Results published in the Psychiatry and Clinical Neurosciences.
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.